Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025
I'm PortAI, I can summarize articles.
Xenon Pharmaceuticals (XENE) announced it will present long-term data on azetukalner at the AAN Annual Meeting in 2025. The data from the X-TOLE study indicates sustained reduction in seizure frequency and high seizure freedom rates in patients with focal onset seizures, highlighting long-term efficacy. The presentation will also cover the mental health impacts of epilepsy and azetukalner's efficacy across seizure subtypes, enhancing its market position. Xenon focuses on developing therapeutics for epilepsy and depression, with azetukalner being their leading candidate. Current market cap is $2.35B, with a YTD price performance of -23.55%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments